AAML1331: A Phase III Study for Patients with Newly Diagnosed Acute Promyelocytic Leukemia (APL) using Arsenic Trioxide and All-Trans Retinoic Acid

Protocol: 
AAAR3160
Phase: 
III

AAML1331: A Phase III Study for Patients with Newly Diagnosed Acute Promyelocytic Leukemia (APL) using Arsenic Trioxide and All-Trans Retinoic Acid

This phase III trial studies tretinoin and arsenic trioxide in treating
patients with newly diagnosed acute promyelocytic leukemia. Standard
treatment for acute promyelocytic leukemia involves high doses of a common
class of chemotherapy drugs called anthracyclines, which are known to cause
long-term side effects, especially to the heart. Tretinoin may stop the
growth of cancer cells by blocking some of the enzymes needed for cell
growth. Arsenic trioxide may stop the growth of cancer cells by either
killing the cells, by stopping them from dividing, or by stopping them from
spreading. Completely removing or reducing the amount of anthracycline
chemotherapy and giving tretinoin together with arsenic trioxide may be an
effective treatment for acute promyelocytic leukemia and may reduce some of
the long-term side effects.

Are you Eligible? (Inclusion Criteria)

-Subjects must be at least 1 year and up to 21 years of age at the time of
study entry.
-Patients must be newly diagnosed with acute promyelocytic leukemia.
-Patients must also meet all eligibility criteria as outlined in the study
protocol.

Trial Location

Herbert Irving Comprehensive Cancer Center
161 Fort Washington Ave.
Herbert Irving Pavilion
New York, NY 10032
United States